Top Markets
Coin of the day
VISEN Pharmaceuticals VISEN Pharmaceuticals

VISEN Pharmaceuticals

2561
Classifica tra le azioni #16898
VISEN Pharmaceuticals operates as an investment holding company, concentrating... VISEN Pharmaceuticals operates as an investment holding company, concentrating on the development and commercialization of endocrine treatments across mainland China, Hong Kong, and Taiwan. Their flagship product, Lonapegsomatropin, offers a once-weekly, long-acting growth hormone replacement designed for pediatric growth hormone deficiency. The company is also progressing other therapies, such as TransCon CNP (navepegritide), a long-acting prodrug utilizing c-type natriuretic peptide for achondroplasia, and Palopegteriparatide, a daily parathyroid hormone replacement therapy intended for chronic hypoparathyroidism. VISEN has forged strategic collaborations with Shanghai Pharmaceutical and United Family Healthcare. The enterprise was founded in 2018 and is based in Suzhou, China.
Prezzo delle azioni
$2.46
Capitalizzazione di mercato
$268.65M
Variazione (1 giorno)
-1.73%
Variazione (1 anno)
-57.06%
Paese
CN
Scambia VISEN Pharmaceuticals (2561)

Categoria

Cronologia dei frazionamenti azionari per VISEN Pharmaceuticals (2561)
L’azione VISEN Pharmaceuticals (simbolo: 2561) ha subito un totale di 0 frazionamenti.
L’ultimo frazionamento è avvenuto il Sep 02, 2026.
Una quota di 2561 acquistata prima di Sep 02, 2026 equivale oggi a 0 quote di 2561.
Elenco dei frazionamenti azionari
Anno Frazionamento Moltiplicatore Moltiplicatore cumulativo
Non abbastanza dati per le date fornite.
Frazionamenti azionari di aziende simili o concorrenti